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Abstract
Thrombospondin 1 (TSP1) has been shown to play a critical role in inhibiting angiogenesis, resulting in inhibition of tumor
growth and metastases. To figure out TSP1’s regulators will lead to reveal its biological function mechanistically. In this
study, we show that E2F-1 could activate the transcription of TSP1 by both promoter assays and Northern blot. Analysis of
various TSP1 promoter mutant constructs showed that a sequence located 2144/2137 up-stream of the transcriptional
initiation site, related to the consensus E2F-responsive sequence, is necessary for the activation. In consistence with up-
regulation of TSP-1 activity by over-expression of E2F-1, the knockdown of endogenous E2F-1 inhibited TSP-1 promoter
activity significantly, implying that E2F-1 mediated regulation of TSP-1 is relevant in vivo. In addition, E2F-1 could also
directly bind to the TSP1 promoter region covering 2144/2137 region as revealed by ChIP assays. Furthermore, the E2F-1-
induced activation of TSP1 gene transcription is suppressed by pRB1 in a dose-dependent manner. Taken together, the
results demonstrate that TSP1 is a novel target for E2F1, which might imply that E2F-1 can affect angiogenesis by
modulating TSP1 expression.
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Introduction
Thrombospondin 1 (TSP1) is a large oligomeric extracellular
matrix glycoprotein that mediates cell-cell and cell-matrix
interactions by binding cell-surface receptors including integrins,
integrin associated protein (IAP)/CD47, CD36, heparin sulfate
proteoglycans, low density lipoprotein related protein 1(LRP1),
and very low density lipoprotein receptor (VLDLR) in addition to
other extracellular matrix proteins, and cytokines [1,2,3,4,5,
6,7,8,9,10]. As the first identified naturally occurring angiogenic
inhibitor, TSP1 has been shown to play a critical role in inhibiting
angiogenesis, resulting in inhibition of tumor growth and
metastases [11,12,13,14]. In consistence with its function in anti-
angiogenesis, TSP1 could inhibit endothelial cells migration in vitro
and induce endothelial cells apoptosis in vivo and in vitro
[8,9,10,15,16,17,18,19]. In addition, the roles of TSP1 in wound
healing, ischemia, heart remodeling, foreign body reaction,
intestinal inflammation and synapse formation have been
recognized [20,21,22,23]. The roles of TSP1 in tumor progression
are closely associated with its regulation by tumor suppressors and
oncogenes. Tumor suppressors including p53, PTEN and smad4
up-regulate TSP1 expression, but the oncogenes including c-jun,
v-src and c-myc down-regulate TSP1 expression [12,24,25,26].
Recently, the identification of gabapentin receptor a2d-1 as a
neuronal thrombospondin receptor re-enforces TSP1’s role in
promoting CNS (Central nervous system) synaptogenesis
[27,28,29]. Targeted overexpression of TSP1 in mice suppressed
wound healing and tumorigenesis, while lack of functional TSP1
resulted in increased vascularization of selected tissues and
significantly decreased the number of excitatory synapses
[13,21,30]. These observations further refined TSP1’s major
functions in vivo.
Taking advantage of cell culture system and zebrafish model, we
have identified that ELL could serve as a transcriptional factor to
directly up-regulate TSP1 expression [31]. ELL was first identified
in acute myeloid leukemia as a translocation partner of MLL. Like
other MLL translocation products, the chimera MLL-ELL
appears to play an important role in leukemogenesis [32,33,
34,35,36]. These findings link the TSP1 with another kind of
cancer progression—leukemogenesis, unrelated to its role in anti-
angiogenesis.
Although the molecular mechanisms of TSP1 in anti-angiogen-
esis, as well as in tumor suppression, have not been well elucidated,
its regulatory factors including either activators or inhibitors seem
to be accounted for acting its role. Therefore, searching for more
up-stream genes of TSP1 might be helpful for uncovering its roles
mechanistically.
In this study, we found that E2F-1 could transactivate TSP1
promoter activity and TSP1 promoter region contains potential
E2F-1 binding consensus sequences. Using promoter assays,
Northern blot and ChIP (chromatin immunoprecipitation) assays,
we identified that E2F-1 could directly transactivate TSP1
expression by binding to its promoter, further expending TSP1’s
regulatory factors.
Materials and Methods
Cell line and plasmid construction
HEK 293 and U2OS cells were obtained from ATCC. Both
cells were maintained in Dulbecco Modified Eagle Medium
(Gibco) with 10% fetal bovine serum (FBS) at 37uC in a humidified
atmosphere containing 5% CO2.
The cDNA of human E2F1 was amplified by PCR and cloned
into the pCGN-HAM (provided by William Tansey), and pCMV-
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pRB1 was amplified by RT-PCR from cDNA pool of 293 cells
and subcloned into pCGN-HAM. Deletion mutants of E2F1 were
generated by PCR and cloned into pCGN-HAM, pCMV-tag 2C
vectors. The TSP1 promoter (22033 to +750) luciferase reporter
was described previously [31]. Deletion mutants of the TSP1
promoter were generated by restriction endonuclease digestion or
PCR and subcloned into the pGL3-Basic vector (Promega). pGL3-
ARF was kindly provided by Gordon Peters. pGL3-CyclinE was
kindly provided by Fred Dick. pGL3-Apaf1 was cloned from total
DNA of 293 cells by PCR using primers: 59-TATCGGTACCAA-
CAAGGCTGGGCTGTTTCCTTCC-39 and 59-TATCAAGC-
TTTACTGGACACAAAGGGAGGAGGTCTT-39.
To accurately map the response region of E2F1 in the TSP1
promoter, four deletion mutants (2413–0, 2293–0, 2173–0,
2113–0) were generated by PCR and subcloned into pGL3-basic
vector at KpnI and XhoI sites. The primers used for PCR were:
TSP1(0)-R, 59- GATACTCGAGGGCAAGGCGGAGGAGCCG-
CGCGCTTTTAAAGGG-39;T S P 1 ( 2413)-F, 59- ATATCGGTA-
CCTCTAGTATCCACCTCTCGCC-39;T S P 1 ( 2293)-F, 59-G A -
TAGGTACCCTTGCTGATCACCCCGAGC-39;T S P 1 ( 2173)-F,
59- GATAGGTACCCCCGCCCCCTTCACTTTCTA-39;a n d
TSP1(2113)-F, 59- GATAGGTACCGAGCCCAGACTGGCCCC-
CAC-39. To further verify E2F-1 binding sites in the promoter of
TSP1, on the basis of TSP1-promoter (2393–0), a series of mutation
constructs (2363-mut, 2238-mut, 2140-mut1, 2363/2238-mut,
2238/2140-mut and 2363/2238/2140-mut) were generated by
PCR and subcloned into pGL3-basic vector at KpnI and XhoI sites.
The mutant (2140-mut2) were generated on the basis of TSP1-
promoter (2173-0). All the constructs were confirmed by sequencing.
To verify E2F-1’s transactivity on TSP1 promoter, an artificial
E2F-1 construct was generated by PCR to clone potential E2F-1
DNA binding domain (aa110–194) into pVP16 vector (Promega)
to form a fusion protein with VP16 transactivation domain (VP-
16-E2F-1(110–194)). The mutant of E2F-1 deficiency in DNA
binding activity (E2F-1(E132)) was generated by PCR and cloned
into pCMV-tag2C vector.
To confirm whether the knock-down of E2F1 has effect on
TSP-1 promoter activity, the siRNA vector targeting for human
E2F1 was constructed using pSUPER according to instructions
[37]. The 19-nt targeting sequence for E2F1 was 59-TATCTG-
TACTACGCAGCTG-39 [38]. U2OS cells growing 6-well plate
were used for verifying E2F-1 knockdown by E2F-1 siRNA using a
monoclonal antibody against E2F-1(Santa Cruz). A siRNA vector
targeting GFP was used as a control.
Luciferase Reporter Assay
293 cells were grown in 24-well plates and transfected with the
indicated amounts of vectors, including pTK-Renilla as an internal
control, by Lipofectamine 2000. Luciferase activity was assayed
16–28 hr after transfection. The luciferase activity in cell extracts
was determined by Dual-luciferase Reporter Assay System
(Promega) according to the protocol supplied by the manufacturer.
The relative light units were measured using a luminometer
(Sirius, Zylux Corporation, Oak Ridge, TN). Data were
normalized to Renilla luciferase. Data are reported as mean 6
SEM of three separate experiments performed in triplicate. The
statistic analysis was performed using t-test (un-paired) embedded
in GraphPad Prism 5.0 Program (GraphPad Software, Inc.).
Western Blot
Anti-GAPDH and anti-E2F1 antibodies were purchased from
Santa Cruz Biotechnology and Anti-HA monoclonal antibody was
purchased from Covance. Anti-Flag antibody was purchased from
Sigma. Western blots were performed as described previously [31].
FujiFilm LAS4000 mini luminescent image analyzer was used to
photograph blots.
Northern Blot
293 cells were transfected with the pCMV-Myc empty vector
(Clontech), or vectors expressing Myc-ELL. Total RNA was
isolated with Trizol reagent (Invitrogen). Electrophoresis, transfer
and hybridization were performed as described previously [31].
Briefly, the membrane was probed using synthesized oligos
corresponding to human TSP1 (59-acaagcaccacatttccagctgccat-
39) and human b-actin (59-atgtgcaatcaaagtcctcggccaca-39) labeled
with biotin at the 39 end. The signal was detected using the
North2South Nucleus Labeling and Detection Kit (Pierce).
Photography and data analysis were done as described for the
Western blot analysis.
Chromatin Immunoprecipitation (CHIP) assay
CHIP assays were performed according to the protocol
described previously [31]. Briefly, 293 cells were fixed in 1%
formaldehyde and then lysed in SDS buffer. Lysates were
sonicated yielding DNA fragments with an average size of 200–
1000 bp and precleared with protein A/G agarose. Then lysates
were immunoprecipitated by 5mg of anti-E2F1 antibody (KH95)
(SC-251, Santa Cruz) or normal mouse IgG (SC-2025, Santa
Cruz). Antibody–nucleoprotein complex mixtures were incubated
overnight and recovered by incubation with 20ml of protein A/G
agarose. Washing, elution, cross-link reversal and purification of
the samples for PCR analysis were performed according to the
protocol described previously. The primers specific for the TSP1
promoter region (2233/0) were: 59- AAGGCTGCGTGGGCG-
GGCAC-39 (forward) and 59-GGCAAGGCGGAGGAGCCG-
CGCGC-30 (reverse). The primers specific for b-actin were
described previously [31].
Results
E2F1 activates TSP1 promoter reporter effectively
When we performed experiments for verifying the specificity of
TSP1 up-regulated by ELL using E2F-1 as a control, we found
E2F-1 could also up-regulate TSP1 promoter reporter efficiently.
In order to define the response elements in TSP1 promoter for
E2F-1 up-regulation, initially, we did fine mapping for TSP1
promoter. Five deletion mutants of TSP1 promoter reporter were
made by PCR and subcloned into pGL3-Basic vector (Fig. 1A).
Subsequently, 6 different length TSP1 promoter reporter
constructs were transfected into 293 cells together with the Renilla
luciferase expression vector as an internal control in the presence
of HA empty vector or HA tagged E2F-1 expression vector, a
series of reporter assays were performed using Dual-luciferase
Reporter Assay System (Promega) according to the protocol
supplied by the manufacturer. The results showed that except for
one mutant (253–750bp), E2F-1 overexpression could activate
other four TSP1 promoter significantly as revealed by statistic
analysis, which suggested that E2F-1 response element was located
the region between 2413 to 253 (Fig. 1B). Interestingly, the TSP1
promoter reporter deleted 0–750 bp region had the highest
activity stimulated by E2F-1, indicating a E2F-1 repression
domain probably located in this region (0–750) (Fig. 1B). Then,
we did dose response experiments for E2F-1 overexpression on
TSP1 promoter activity. Flag empty vector or different dose of
Flag-tagged E2F-1 expression vector, TSP1(22033,0) promoter
reporter and Renilla luciferase expression vector were co-
transfected into U2OS cells. As shown in Fig. 1C, the TSP-1
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amounts of E2F1 expression vector. The expression of different
amounts of Flag-tagged E2F1 was verified by Western blot
(Fig. 1D). These results not only further confirmed the up-
regulation of TSP-1 by E2F-1 effectively, but also ruled out the
non-specific up-regulation of TSP-1 promoter activity as a result of
ectopic expression of large amount of E2F-1 expression vector.
Furthermore, to get a clear picture about the importance of E2F-
1’s effect on TSP-1 up-regulation, we chose three other well-
known E2F-1 targeting genes’ promoter luciferase reporters
including ARF, Apaf1 and Cyclin E for evaluation. As judged
by luciferase activity measurements, the transactivity of E2F-1 on
TSP-1 promoter was lower than that of ARF, but higher than that
of Cyclin E, which is similar to that of Apaf-1 (Fig. 1E). In
addition, we did further fine domain mapping for the region 2413
to 0 of TSP1 promoter (Fig. 1F). The results indicted that E2F-1
response elements were located in the region between 2173 to
2113 (Fig. 1G). The expression of HA-tagged E2F-1 (0.2mg
vector/per well transfected into 293 cells growing in 6-well plate)
was verified by Western blot using a monoclonal antibody against
HA (Fig. 1H).
As a transcription activator, E2F1 can bind DNA cooperatively
with DP proteins through the E2 recognition site (59-
TTTC[CG]CGC-39 ) located in the promoter region of a number
of genes whose products are involved in cell cycle regulation or in
DNA replication [39]. After searching for the consensus sequences
Figure 1. E2F-1 activates TSP1 promoter. A, schematic depiction of six TSP1 promoter deletion constructs in the region 22033 to +750bp. The
transcription initial site is designated as +1. B, quantification of E2F-1 transcriptional activity on six TSP1 promoter constructs. 293 cells were used for
assays and 0.2 mg HA tagged E2F-1/per well was used for transfection in 24-well plates. C, dose response of E2F1 on TSP1 promoter activity in U2OS
cells. D, the expression of different doses of Flag-tagged E2F1 was verified by Western blot using anti-flag monoclonal antibody, the amounts of Flag-
E2F-1 for transfection were indicated. E, the promoter luciferase reporters of E2F1 targeted gene ARF, Apaf1 and CyclinE were used as controls to
evaluate the transcriptional activity of E2F-1 on TSP1 promoter, 0.2 mg HA tagged E2F-1/per well was used for transfection in 24-well plates. F,
schematic depiction of four TSP1 promoter deletion constructs in the region 2413 to 0 bp. G, quantification of E2F-1 transcriptional activity on four
TSP1 promoter constructs, 0.2 mg HA tagged E2F-1/per well was used for transfection in 24-well plates. H, the expression of HA-tagged E2F-1 was
verified by Western blot using anti-HA monoclonal antibody.
doi:10.1371/journal.pone.0013442.g001
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presented in TSP1 promoter region between 2363 to 2137
(Fig. 2A). In order to determine whether these E2F-1 binding sites
in TSP1 promoter were responsible for E2F-1 up-regulation, we
made substitution mutations for the region 2393 to 0 of TSP1
promoter (Fig. 2B). Then, Flag empty vector or Flag-tagged E2F1
(0.2 mg/per well in 24-well plates) was co-transfected into 293 cells
along with mutant constructs and Renilla. The results from
promoter assays showed that 2363-mut and 2238-mut could
partially reverse the transcription activity of E2F1, but 2140-mut
almost completely reverse the transactivation of E2F1 (Fig. 2C).
When the three putative binding sites were mutated simulta-
neously, the transactivation of TSP1 induced by E2F1 was
abolished completely. In addition, the short mutant 2140-mut2
also lost its responding for E2F-1 up-regulation, further confirming
that the consensus binding site located between 2144 to 2137 was
critical for E2F-1 responding.
To further test whether E2F1 DNA binding domain was critical
for transactivating TSP1, the potential DNA binding domain
(110–194 amino acids) was fused with VP16 activation domain
using pVP16 vector (Clontech). Subsequently, we co-transfected
VP16-E2F1 (110–194) (0.2 mg/per well in 24-well plates) along
with TSP1 promoter luciferase reporters TSP1 (22033 to 0 ),
TSP1(2173 to 0) or TSP1 (2140-mut2 ) respectively. The
luciferase assays showed that VP16-E2F1-(110–194) could indeed
transactivate the TSP1 promoter reporters significantly
(p,0.0001) but not TSP1 (2140-mut2) (Fig. 2E). Moreover, the
E2F-1 mutant (E132) lacking DNA binding activity failed to
transactivate TSP1 promoter (22033 to 0) (Fig. 2F). These
observations suggested that the DNA binding activity of E2F1 is
required for inducing TSP1 expression. The expression of Flag-
tagged wild-type E2F-1 and the mutant (E132) were verified by
Western blot (Fig. 2G) using anti-Flag antibody. In addition, in
order to test whether pRB1 could affect the transactivation of E2F-
1 on TSP1 promoter, we transfected two different dosage of HA-
tagged pRB1 (0.2mg and 0.5mg/per well in 24-well plates) together
with HA-tagged E2F-1(0.2 mg/per well in 24-well plates) and
performed promoter assays, pRB1 could indeed suppress the
transactivity of E2F-1 on TSP1 promoter in a dose-dependent
manner (Fig. 2H), which is consistent with the effect of pRB1 on
other bona fide targets of E2F-1. At the same time, different
function domains of E2F1 were cloned into Flag-tagged vector and
co-transfected into 293 cells with TSP1 promoter luciferase
reporter TSP1(22033 to 0). The luciferase assay showed that
only full length E2F1 can up-regulate TSP1 (22033 to 0) (Fig. 2I).
The expression of different function domains of E2F1 were
verified by Western blot (Fig. 2J).
To figure out whether endogenous E2F1 could still have some
influence on TSP1 promoter activity, we knocked down the
expression of endogenous E2F-1 by an E2F1-specific short
interfering RNA (siRNA) vector into U2OS cells. As expected,
compared to the control (cells transfected with a siRNA vector
specifically targeting GFP expression), E2F-1 knockdown could
inhibit TSP-1 promoter (22033, 0) activity significantly
(p=0.0001) (Fig. 2K). The knockdown of endogenous E2F1 was
confirmed by Western blot (Fig. 2L). The observations suggested
that E2F-1-mediated regulation of TSP-1 is physiologic relevant.
E2F1 binds to the TSP1 promoter in vivo
To demonstrate whether the action of E2F1 on TSP1 occurs in
vivo, we conducted chromatin Immunoprecipitation assay to test
the binding of E2F1 in the TSP1 promoter. As shown in Fig. 3B,
an enrichment of the TSP1 promoter was detected using anti-
E2F1 antibody in 293 cells. No signal was observed using a
negative control antibody (normal mouse IgG). Primers specific for
b-actin was used as control. These results indicated that E2F1
could bind to the TSP1 promoter directly in 293 cells.
E2F1 up-regulates TSP1 mRNA expression
We next want to test whether E2F1 could up-regulate
expression of the endogenous TSP1 gene. Total RNA was
extracted from 293 cells 24h after transfected by either HA-
E2F1 expression vector or equivalent control empty vector. Up-
regulation of TSP1 mRNA by E2F1 was confirmed by Northern
blot analysis (Fig. 4) which suggested that E2F1 could indeed
induce TSP1 mRNA expression.
Discussion
In this study, through domain mapping for TSP1 promoter, we
identified that the E2F-1 binding consensus sequence located in
2144 to 2137 of TSP1 promoter is critical for E2F1 up-
regulation. Further ChIP assays confirmed that E2F-1 could bind
the promoter region covering 2144 to 2137 in vivo. These
observations suggested that E2F-1 could regulate TSP1 expression
by directly binding to its promoter. In addition, we verified that
the DNA binding domain and DNA binding ability of E2F-1 were
required for transactivating TSP1 expression. Furthermore, we
found that the knockdown of endogenous E2F-1 could inhibit
TSP-1 promoter activity significantly, confirming the relevance of
E2F-1 mediated regulation of TSP-1 in vivo. Taken together, these
results suggested that TSP1 is a direct target of E2F-1.
E2F-1 belongs to a large family of transcription factors
containing one or more conserved DNA binding domains (DBDs)
that bind target promoters and regulate their expression
[40,41,42]. To elucidate E2F-1’s function, searching for E2F-1’s
bona fide targets has been extensively conducted. Through global
gene expression profiling and promoter occupancy arrays, many
Figure 2. E2F-1 binding site in TSP1 promoter is required for E2F-1 up-regulation. A, the partial sequence of TSP1 promoter (2393 to
+27bp). Three potential E2F-1 binding sites were marked by boxes and substitution mutations in those sites were indicated underline. B, schematic of
eight TSP1 promoter mutation constructs in the region 2393 to 0bp. The three potential E2F-1 binding sites were marked by dark circles and
mutations were marked by ‘‘X’’. C, quantification of E2F-1 transcriptional activity on eight TSP1 promoter mutation constructs, 0.2 mg Flag tagged
E2F-1/per well was used for transfection in 24-well plates. D, schematic depiction of E2F-1 DNA binding region (amino acid 110–194) cloned into
pVP16 vector. E, quantification of E2F-1 transcriptional activity on three TSP1 promoter mutants, 0.2 mg VP-16E2F-1(110–194) or VP-16/per well was
used for transfection in 24-well plates. F, quantification of wild-type E2F-1 and E2F-1(E132) transcriptional activity on TSP1 promoter (22033–0)
luciferase reporter, 0.2 mg vector/per well was used for transfection. G, the expression of HA-tagged wild-type E2F-1 and E2F-1 DNA binding site
mutant (E132) was verified by Western blot using anti-Flag monoclonal antibody. H, quantification of pRB influence on E2F-1 transcriptional activity
on TSP1 promoter (22033–0) luciferase reporter construct, the expression of HA tagged human pRB was verified by Western blot and the amounts of
HA-pRB for transfection were indicated. I, quantification of E2F-1 deletion mutants on TSP1 promoter (22033–0) luciferase reporter construct. J, the
expression of flag-tagged E2F-1 deletion constructs was verified by Western blot using anti-Flag monoclonal antibody, 0.2 mg different construct/per
well was used for transfection. K, quantification of E2F-1 siRNA on TSP1 promoter (22033–0) luciferase reporter activity. L, the knockdown of E2F1 by
siRNA in U2OS cells was verified by Western blot using anti-E2F1 monoclonal antibody, a siRNA targeting GFP was used as control, 0.6 mg siRNA
expression vector/per well targeting E2F-1 or GFP was used for transfection in 6-well plates.
doi:10.1371/journal.pone.0013442.g002
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progression have been identified, which established a direct role
for E2F-1 in governing cell proliferation [41,43,44]. Moreover, the
roles of E2F-1 in cancer have been well-recognized due to its
association with pRB1— a classic tumor suppressor. The pRB1
tumor suppressor directly associates with E2F-1 to modulate gene
expression, either inhibit its transactivation or enhance its
suppressive function [43,44,45,46]. Functional inactivation of
pRB1 in various human cancers leads to deregulated E2F1
activity [46]. Here, we presented data to show that pRB1 could
also suppress E2F-1’s transactivity on TSP1 promoter in a dose-
dependent manner, which is consistent with the role of pRB1 in
modulating expression of E2F-1 targets, further confirming that
TSP1 serves as a bona fide target of E2F-1.
The role of genes in anti-angiogenesis represents a major aspect
for their function in tumor suppression [47]. Even though, the
roles of E2F-1 in tumor progression have been extensively
investigated, however, to date, little is known about its function
relevant to angiogenesis. TSP1 is the first identified naturally
occurring angiogenic inhibitor, its role in inhibiting angiogenesis,
resulting in inhibition of tumor growth and metastases has been
well-defined [11], and therefore, the identification of TSP1 as a
direct target of E2F-1 might open a new window for demonstrat-
ing the role of E2F-1 on anti-angiogenesis, relevant to its function
in tumor suppression. Of cause, how E2F-1 acting its role in anti-
angiogenesis through the regulation of TSP1 expression is
definitely worth to be further investigated.
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